PGT-M and PGT-SR Billing: Genetic Testing Code Selection

When most fertility billing teams think about preimplantation genetic testing, they think about PGT-A — aneuploidy screening for chromosome count abnormalities. But PGT-M (testing for single-gene disorders) and PGT-SR (testing for structural chromosomal rearrangements) are fundamentally different billing scenarios. The clinic-side biopsy codes are the same, but the genetics lab codes, the ICD-10 diagnosis codes, the prior authorization documentation, and the insurance benefit category used to adjudicate the claim can all differ significantly from PGT-A. Billers who apply PGT-A workflows to PGT-M or PGT-SR cycles consistently produce claims that deny on first pass and require intensive corrective action.

PGT-M vs. PGT-SR: The Clinical Distinction That Drives the Billing Difference

PGT-M tests embryos for a specific gene mutation known to cause a single-gene disorder — cystic fibrosis, BRCA1/2 mutations, sickle cell disease, Huntington's disease, spinal muscular atrophy, fragile X syndrome, and hundreds of other heritable conditions. One or both partners are carriers or are affected, and the goal is to identify embryos that either do not carry the pathogenic variant or carry it in a configuration the family deems acceptable for transfer. PGT-M requires a custom assay designed specifically for the family's mutation before the IVF cycle even begins — the genetics lab must design and validate the probe against DNA samples from the couple and sometimes additional family members. This pre-cycle assay design step is billable, has a lead time of several weeks, and is a common source of missed charges at clinics that lack a formal PGT-M billing protocol.

PGT-SR tests embryos for chromosomal structural rearrangements — balanced translocations, Robertsonian translocations, chromosomal inversions, and insertions. Carriers of a balanced rearrangement are typically phenotypically normal but have a significantly elevated risk of producing embryos with unbalanced chromosomal material, which manifests clinically as recurrent pregnancy loss or repeated IVF failure. PGT-SR identifies embryos that are chromosomally normal or balanced carriers — both of which are suitable for transfer — and distinguishes them from embryos with unbalanced chromosomal content. The testing methodology for PGT-SR is more similar to PGT-A than to PGT-M, because both PGT-A and PGT-SR rely on comprehensive chromosome analysis rather than gene-specific probes. This similarity affects the genetics lab code selection and the prior authorization pathway in ways billers need to understand.

Clinic-Side Biopsy Codes: Identical Across All Three PGT Types

The embryo biopsy procedure performed at the IVF clinic is identical regardless of whether the indication is PGT-A, PGT-M, or PGT-SR. Trophectoderm biopsy of a blastocyst is the same clinical act in all three testing types, and the CPT codes follow the same embryo-count selection rules. All PGT-M and PGT-SR cycles are also freeze-all cycles — embryos are vitrified while awaiting genetic results, because turnaround from the genetics lab typically takes 5 to 14 days for PGT-A and 7 to 21 days for PGT-M depending on assay complexity. The subsequent FET cycle is billed as a separate and distinct billing event from the biopsy encounter.

Genetics Lab Codes for PGT-M: Why Most Claims Use 81479

PGT-M requires a custom-designed assay specific to the family's mutation. The genetics reference lab designs a probe or panel that targets the precise pathogenic variant carried by the couple, then validates it before the cycle begins. Because each PGT-M assay is bespoke, the testing methodology often cannot be accurately described by any existing CPT code — which is why most PGT-M submissions from genetics labs use CPT 81479 (unlisted molecular pathology procedure). When 81479 is used, the claim must be accompanied by supporting documentation describing the methodology, the gene tested, the specific variant, and the number of embryos analyzed. Without this documentation, 81479 processes as an unspecified service and typically denies on medical necessity grounds.

However, when PGT-M is performed for a condition that has a recognized CPT code in the molecular pathology series, the genetics lab should use that specific code rather than 81479. Using an unlisted code when a specific code exists is a coding error that can trigger underpayment or a medical necessity audit. Billing teams should confirm with their genetics reference lab which specific code the lab intends to submit for each PGT-M cycle — and verify that the code matches the authorization obtained — before the cycle proceeds. A mismatch between the authorized code and the billed code, even when both describe the same service, generates a denial at many commercial payers.

Genetics Lab Codes for PGT-SR: Overlap With PGT-A

PGT-SR uses comprehensive chromosome analysis methodology that is conceptually similar to PGT-A — the goal is to identify unbalanced chromosomal content across the whole genome rather than to detect a specific single-gene mutation. Because of this methodology overlap, PGT-SR and PGT-A share many of the same genetics lab CPT codes. The billing distinction between PGT-A and PGT-SR at the analysis code level is driven primarily by the ICD-10 indication and the prior authorization documentation, not by a different code set. This is an important point for billing teams: do not assume that PGT-SR requires entirely different genetics lab codes — focus on the ICD-10 and authorization differences, where the two testing types truly diverge.

ICD-10 Code Selection for PGT-M and PGT-SR Claims

ICD-10 code selection for PGT-M and PGT-SR is considerably more complex than for PGT-A. The diagnosis must capture both the infertility indication for the ART cycle and the specific genetic condition that justifies the preimplantation testing. Submitting a non-specific infertility code (N97.9) alone — already inadequate for PGT-A — is particularly problematic for PGT-M, where the clinical driver is a known pathogenic gene variant in the family and where payer medical necessity review specifically evaluates whether the documented genetic condition meets coverage criteria. The ICD-10 codes on the claim must reflect the same specificity used in the prior authorization request.

Prior Authorization: Where PGT-M and PGT-SR Differ Most From PGT-A

Prior authorization for PGT-M is substantially more documentation-intensive than PGT-A — and insurance coverage for PGT-M is far less consistent. For PGT-A, a payer that covers PGT will typically evaluate the clinical indication based on maternal age, prior failed cycles, or pregnancy loss history. For PGT-M, the payer must additionally evaluate whether the specific genetic condition meets their medical necessity criteria for preimplantation testing, whether the testing methodology is covered under their laboratory or molecular genetics benefit (often a different benefit category than the fertility benefit), and whether the genetics reference lab is in-network under the applicable benefit. Many commercial plans that cover PGT-A explicitly exclude PGT-M as a genetic selection or reproductive enhancement service — this exclusion must be identified during benefit verification before the patient begins any part of the cycle.

PGT-SR prior authorization is structurally closer to PGT-A because the testing methodology is chromosomal rather than gene-specific. Payers that cover PGT-A for chromosomal conditions will often extend coverage to PGT-SR when the partner's confirmed structural rearrangement is documented. The authorization request for PGT-SR should include the karyotype report from the affected partner and, when the clinical indication is recurrent pregnancy loss, documentation of prior pregnancy losses with any available pathology or chromosomal testing results attributable to unbalanced chromosomal material.

• Verify separately whether the plan covers PGT-M and PGT-SR — a plan that covers PGT-A may explicitly exclude PGT-M, and a plan that excludes PGT-A may still cover PGT-SR under a chromosomal abnormality benefit. Do not assume coverage from one testing type extends to another without specific verification.
• Confirm the benefit category: PGT-M genetic analysis is frequently processed under the laboratory benefit or molecular genetics benefit rather than the fertility benefit. Authorization must be routed to the correct benefit administrator. Submitting to the fertility benefit manager when the analysis adjudicates under the lab benefit results in an authorization that is valid for the wrong service category and will not protect the genetics lab's claim at adjudication.
• Obtain authorization for the pre-cycle assay design: for PGT-M, the genetics lab must design and validate the custom probe before the IVF cycle begins. Some payers require a separate authorization for this design and validation service before it is performed. Confirm whether this pre-cycle component requires authorization — missing it creates an unbillable lab service and delays the cycle while authorization is retroactively sought.
• List the genetics reference lab's name and NPI in the authorization request: many payers require PGT analysis to be performed at a specific in-network genetics laboratory. If the authorization does not identify the specific lab, claims from that lab may not be recognized as authorized at adjudication even when a valid auth number exists.
• Request separate FET authorization proactively: the biopsy and analysis authorization does not cover the subsequent frozen embryo transfer cycle. Each FET following PGT-M or PGT-SR requires its own standalone authorization covering 89352, 58976, and the endometrial monitoring codes. Initiate the FET authorization as soon as genetic results are available so the authorization window covers the anticipated transfer date.
• Verify authorization window against PGT-M assay lead time: PGT-M assay design typically requires 4 to 6 weeks before the IVF cycle can begin. An authorization issued before assay design is completed may expire before the cycle starts if the design process encounters delays. Confirm the authorization effective dates cover the projected cycle start date, and request extension proactively if the design timeline slips.

Documentation Required for PGT-M Authorization Requests

PGT-M authorization requests require documentation that significantly exceeds what a standard IVF prior authorization includes. The payer's medical director will evaluate whether the genetic condition meets their medical necessity criteria for preimplantation testing. Submitting a generic request without the required supporting documentation virtually guarantees a delay or denial at the authorization stage. Compile and attach all of the following before submitting the authorization request for any PGT-M cycle.

• Genetic testing results confirming carrier or affected status in both partners: the payer needs independently verified documentation of the genetic indication in the clinical record. A clinical summary or physician attestation alone is insufficient — attach the original laboratory reports from the genetic testing that identified the pathogenic variant in each partner.
• Pedigree or family history documentation showing the condition's inheritance pattern: particularly critical for autosomal recessive conditions (where both partners must be confirmed carriers), autosomal dominant conditions (where typically only one partner is affected or a carrier), and X-linked conditions. The pedigree supports medical necessity by establishing the inheritance risk to offspring.
• Consultation note from a board-certified genetic counselor: most commercial payers require documentation of formal genetic counseling as a pre-condition of PGT-M authorization. The note must document the session date, the condition discussed, the inheritance risk calculation, the options presented to the couple, and the patient's informed decision to proceed with PGT-M.
• Genetics reference lab confirmation of assay feasibility: the PGT-M laboratory must confirm that a custom probe can be designed for the family's specific mutation variant before authorization is requested. Some payers require a letter from the genetics reference lab confirming assay feasibility and the projected timeline as a condition of authorization.
• Complete CPT code list for all services across the cycle: the authorization must explicitly list every code that will appear on any claim associated with the PGT-M cycle — including the biopsy codes (89290 or 89291), the embryology codes (89258), the genetic analysis code (81479 or the applicable gene-specific code), and the FET codes (89352, 58976). Authorization that lists only the fertility procedure codes but omits the genetic analysis codes will not cover the genetics lab's claim at adjudication.
• ICD-10 codes matching the genetic condition and ART encounter: the condition-specific code for the genetic disorder (Z14.x for carrier conditions, Z15.x for susceptibility conditions, Q95.x for structural rearrangements) must be listed in the authorization exactly as it will appear on the claim. Mismatch between authorization diagnosis codes and claim diagnosis codes is one of the most common causes of PGT-M claim denial despite a valid authorization.

Top Denial Reasons for PGT-M and PGT-SR Claims

• PGT-M categorically excluded under the plan benefit: many commercial plans explicitly exclude genetic selection or reproductive enhancement services from their fertility benefit. This exclusion does not appear on the insurance card and is only discoverable through specific verification of the plan's genetic testing benefit. When the exclusion exists, billing to the plan produces a denial with no viable appeal path unless the patient's state has enacted a mandate that requires PGT-M coverage.
• Biopsy code selection error (89290 vs. 89291): selecting 89291 when fewer than 5 embryos were biopsied, or 89290 when 5 or more were biopsied, creates a discrepancy between the claim and the embryology lab record. Payers that cross-reference documentation will flag the mismatch on first pass or during post-payment audit.
• Clinic bills genetic analysis codes (81479, 81228, or gene-specific codes): genetic analysis codes belong exclusively on the genetics lab's claim. When these codes appear on the IVF clinic's claim simultaneously with the genetics lab's submission, payers identify the duplication and initiate refund recovery against both entities — often covering the prior 12 months of paid claims.
• Authorization does not list genetic analysis codes: IVF authorization that approves retrieval (58970) and biopsy (89290 or 89291) but omits the genetic analysis codes (81479 or applicable molecular pathology code) will not protect the genetics lab's claim at adjudication. The genetics lab's submission then denies as not authorized, typically arriving weeks after the biopsy claim paid — creating a delayed denial that requires coordination between the clinic, the genetics lab, and the payer.
• Genetics reference lab is out-of-network: PGT-M assay design requires specialized expertise available at relatively few reference laboratories. Patients may be directed to a specific genetics lab with no in-network contract under their plan. Out-of-network genetics lab claims for PGT-M are one of the primary sources of unexpected patient balance disputes in fertility billing — and for some payers, the claims result in full denial rather than out-of-network reimbursement at any level.
• Missing genetic counseling documentation: payers that cover PGT-M routinely require evidence of pre-cycle genetic counseling completion as a coverage condition. A claim submitted without documentation of completed genetic counseling — or an authorization request that did not include the counseling note — gives the payer grounds to deny on a coverage condition basis regardless of whether other medical necessity criteria are met.
• ICD-10 code mismatch between authorization and claim: when the authorization was issued using one set of diagnosis codes and the claim arrives with different codes — even if the substituted codes are more clinically specific — many commercial payers trigger a mismatch denial. This is especially common in PGT-M when billing staff substitute a gene-specific Z14.x or Z15.x code on the claim that differs from a more general code used at the authorization stage. Always match claim diagnosis codes to the codes listed in the authorization.
• PGT-SR claim submitted to fertility benefit without documenting the structural rearrangement: payers that adjudicate PGT-SR under a chromosomal abnormality benefit rather than the fertility benefit will not process the claim correctly if it is routed to the fertility benefit administrator. Confirm the correct benefit pathway for PGT-SR at your major payers during eligibility verification — the routing distinction is not always intuitive.

The FET Cycle Following PGT-M or PGT-SR

Every PGT-M and PGT-SR cycle results in a freeze-all — the biopsied embryos are vitrified while awaiting genetic results. When results return and an embryo is confirmed unaffected (PGT-M) or chromosomally normal or balanced (PGT-SR) and suitable for transfer, the patient proceeds to a frozen embryo transfer cycle. This FET is billed identically to any other FET: CPT 89352 for the embryo thaw, CPT 58976 for the frozen embryo transfer, and the applicable endometrial monitoring codes — 76830 (transvaginal ultrasound) billed on each monitoring date, 82670 (estradiol) and 84144 (progesterone) for hormone assays performed during the preparation phase.

What changes at the FET stage is the authorization: the FET following PGT-M or PGT-SR requires a standalone prior authorization entirely separate from the biopsy cycle authorization and the genetics analysis authorization. The FET authorization request should reference the same infertility and genetic condition ICD-10 codes used throughout the prior cycle documentation, and should include — where the payer requires it — documentation that the embryo to be transferred was confirmed unaffected or chromosomally normal by PGT. On the FET claim itself, use the patient's underlying infertility and genetic condition diagnosis codes and add Z31.83 as an additional code. Do not use the PGT result as a claim-level ICD-10 code. There is no ICD-10 code for "euploid embryo," "unaffected embryo," or "confirmed carrier embryo" — these are clinical laboratory classifications that belong in the procedure note as narrative context, not in the claim data structure.

PGT-M and PGT-SR billing requires more cross-entity coordination, more detailed authorization documentation, and more precise ICD-10 code selection than any other service category in fertility revenue cycle management. Practices that lack an explicit PGT-M and PGT-SR billing protocol — covering pre-cycle assay authorization, biopsy claim submission, genetics lab billing coordination, and FET follow-through — will experience denial rates above 30% on first pass for these services. The revenue at stake per cycle is significant: a PGT-M cycle that includes assay design, biopsy, genetic analysis, and a subsequent FET can represent $8,000 to $15,000 or more in total billings across the clinic and the genetics reference lab. Building a repeatable, payer-specific protocol for PGT-M and PGT-SR is not a process improvement opportunity — it is a revenue protection requirement.